Cimzia AutoClicks 200 mg, solution injectable en stylo prérempli

( ARTG ) Rheumatoid arthritis Cimzia is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients. Combined with MTX in case of either an inadequate response or intolerance to previous therapy with one or more disease modifying antirheumatic drugs (DMARDs) or As monotherapy in case of a contraindication or intolerance to MTX (see Section 4.2 Dose and Method of Administration). Cimzia has been shown to reduce the rate of progression of joint damage as measured by X-ray, when given in combination with MTX. Cimzia in combination with MTX is indicated for the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX or other DMARDs. Psoriatic arthritis Cimzia is indicated for the treatment of adult patients with active psoriatic arthritis where response to previous disease modifying antirheumatic drug therapy (DMARDs) has been inadequate. Cimzia has been shown to improve physical function.,Ankylosing spondylitis Cimzia is indicated for the treatment of adult patients with active, ankylosing spondylitis who have been intolerant to or have had inadequate response to at least one nonsteroidal anti-inflammatory drug (NSAID).,Non-radiographic Axial Spondyloarthritis Cimzia is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C reactive protein (CRP) and /or magnetic resonance imaging (MRI) change, who have had an inadequate response to, or are intolerant to, nonsteroidal anti-inflammatory drugs (NSAIDs).,Plaque psoriasis Cimzia is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.